AbbVie takes $2.1 billion charge on cancer drug ahead of US price negotiation
By Leroy Leo and Christy Santhosh (Reuters) -AbbVie, girding for government price negotiations on its big-selling cancer drug Imbruvica, on Friday disclosed a $2.1 billion charge related to an expected drop in revenue once the new price for U.S. Medicare patients goes into effect. The Illinois-based drugmaker’s leukemia pill in August was selected as one…
